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Chest CT for suspected pulmonary




In cancer patient during or following oncologic therapies with respiratory symptoms and pulmonary pathology at
chest CT the differential diagnosis includes infection, therapy-induced disease and tumour progression.
Although CT morphology may be typical or even pathognomonic in some conditions the diagnosis is usually made
by a synopsis of imaging, clinical and laboratory features.
Close communication with referring colleagues and a good knowledge of potential side effects of therapeutic
concepts, their time course and CT morphology is crucial in the differential diagnosis.
This review describes a personal approach to the radiological diagnosis of therapy-induced pulmonary
abnormalities in cancer patients.
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Background
Why imaging for pulmonary complications of oncologic
therapy?
In patients during or following therapy for cancer pul-
monary symptoms are common. These may, obviously,
be due to a variety of causes such as progression of ma-
lignancy involving the chest as well as infectious or non-
infectious complications of surgery, radiation or medical
therapy. In addition, in cancer patients disease unrelated to
malignancy may occur, although the risk for some of these
conditions may be increased due to the disease or its
therapy.
The different potential causes of chest symptoms
may require completely different therapeutic ap-
proaches. Escalation or change of chemotherapy or
molecular therapy may be required in progressive
disease but may have catastrophic results in pulmon-
ary toxicity of these drugs. Steroid therapy is usually
indicated in non-infectious inflammatory compli-
cations but may aggravate pulmonary infection.
Antimicrobial treatment is obviously useful in
infectious complications but its toxicity particularly
of antifungal therapy may be detrimental in cases of
non-infectious disease. Unnecessary discontinuation
of an effective drug will obviously result in a nega-
tive effect for the patient.
Furthermore, in cancer patients pulmonary disease
may have a more aggressive and potentially lethal course
than in otherwise healthy patients.
For all these reasons it is mandatory to establish the
cause of the pulmonary symptoms fast and reliably.
The clinical signs and symptoms of pulmonary
disease such as cough, dyspnoea, hypoxia and signs
of inflammation are usually unspecific and do not
reliably allow differentiation between the different
conditions.
Laboratory test alone are usually not specific enough
for patient management. Therefore, imaging is crucial
in these circumstances and has a major impact on
therapeutic decisions.
This review describes a personal approach to the radio-
logical diagnosis of therapy-induced pulmonary abnormal-
ities in cancer patients. It does not claim to cover all
aspects of the problem and specifically does not include
post-surgical changes.
Correspondence: stefan.diederich@vkkd-kliniken.de
Department of Diagnostic and Interventional Radiology, Marien Hospital,
Academic Teaching Hospital, Rochusstr. 2, D- 40479 Düsseldorf, Germany
© 2016 Diederich. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Diederich Cancer Imaging  (2016) 16:7 
DOI 10.1186/s40644-016-0066-4
Risk considerations: assessing pre-test probability
of different pulmonary complications
As almost all imaging findings in pulmonary complica-
tions are not specific enough to decide on the significant
therapeutic consequences on the basis of imaging results
alone it is of paramount importance to use a synopsis
of clinical laboratory and imaging data to make the
diagnosis.
Pulmonary disease in oncologic therapy
Radiation pneumonitis
Radiation of pulmonary parenchyma exceeding a dose of
30–40 Gray (Gy) usually leads to radiation pneumonitis
which may be clinically occult but may also present with
symptoms such as unproductive cough, dyspnoea and
clinical and laboratory signs of inflammation.
Radiation pneumonitis follows a rather typical time
course: 6–10 weeks after the radiation dose threshold
has been exceeded ground glass is observed which then
increases in density to present as consolidation. After
some months fibrosis occurs with a decrease in volume
of the involved lung area and signs such as traction
bronchiectasis and displacement such as interlobar fis-
sures, vessels and bronchi.
Radiation pneumonitis almost exclusively involves the
lung area that was affected by radiation dose above the
threshold and is not limited by anatomical borders such
as interlobar fissures.
It is relatively easy to make a diagnosis of radiation
pneumonitis in simple radiation ports as there is usually
a sharp border between involved and normal lung fol-
lowing the borders of the radiation port [1,2]. If, how-
ever, more modern radiotherapy techniques are used
(e.g. intensity-modulated radiation therapy (iMRT),
gamma-knife, cyber-knife) it may be impossible to estab-
lish the diagnosis unless the dose distribution is known
(Fig. 1). Ideally, radiation planning data should be avail-
able to the diagnostic radiologist in these patients.
Drug-induced pulmonary toxicity
A large variety of drugs is used in modern systemic ther-
apy of malignancy and usually combinations of two or
more drugs are administered in order to increase the ef-
ficacy without increasing toxicity. Classical cytotoxic
chemotherapy, leading to cell tumour necrosis may be
combined with molecular therapy that blocks cell me-
tabolism, blood supply and other cellular functions with-
out actually destroying the tumour cells. Most recently
immune therapy has been introduced in which the host’s
immune response to the malignant cells is enhanced [3].
Many of these agents have side effects that may
manifest in the lung. Due to the fact that there are
innumerable combinations of different drugs with differ-
ent doses it is very difficult to predict potential toxic ef-
fects in the lung. Furthermore, the spectrum of drug-
induced pulmonary disease is not unique but represents
Fig. 1 Radiation pneumonitis. Patient with NSCLC (non-small cell lung cancer) treated with radiation. a Dose distribution at radiation planning
simulation. b Chest CT at lung window with consolidation. Note the tongue-like area of consolidation in the anterior segment of the left upper
lobe reflecting the area with > 75 % of the total dose at the dose distribution plan
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a spectrum of diseases which also occurs unrelated to
drug toxicity.
It includes hypersensitivity pneumonitis, interstitial
pneumonitis with a pattern of non-specific interstitial
pneumonia (NSIP) (Fig. 2), cryptogenic organizing pneu-
monia (COP), pulmonary haemorrhage, pulmonary
oedema, bronchiolitis, vasculitis and many others.
Finally, one drug may cause several different patterns
of pulmonary toxicity. Therefore, it is almost impossible
to know all possible patterns of drug-induced lung disease
even in the commonest therapeutic regimens. There is a
very helpful freely available website which lists all potential
effects of a large variety of drugs (not only in oncology)
which is regularly updated (http://www.pneumotox.com).
The website does not present radiological images but lists
potential patterns.
Infection: predisposing factors for infection with different
organisms
Obviously, immunosuppression due to malignancy
(e.g. lymphoma, leukaemia) or its therapy (particularly
chemotherapy, molecular therapy) often increases the
risk of pulmonary infection.
Furthermore, depending on the affected cell line and
other factors the risk for infection with specific organisms
differs. If these conditions are taken into account it is
possible to estimate whether a patient is more likely to
develop bacterial, fungal, viral infection.
There is however, an overlap and a combination of
infection with different organisms at the same time is
not uncommon (Table 1) (Figs. 3, 4, 5 and 6).
Other disease with increased risk in cancer patients
Cryptogenic organizing pneumonia (COP) manifests
as solitary or multiple peripheral areas of consolidation,
pulmonary nodules or masses, peribronchovascular con-
solidation or other morphology.
It may occur secondary to infection, therapy with dif-
ferent drugs, collagen vascular diseases or with no
known cause (idiopathic COP).
In cancer patients it may be a manifestation of drug-
induced lung disease. It is also associated with radiation
therapy. Other than radiation pneumonitis the lung ab-
normalities are not confined to the radiation port and
the time course is variable with COP occurring weeks or
months after radiation therapy [4].
Deep venous thrombosis (DVT) leading to pulmon-
ary embolism (PE) is more common in cancer patients
than in patients with no malignancy. It may be due to
the cancer (e.g. particularly increased risk in pancreatic
cancer) or its therapy (e.g. antihormonal therapy in hor-
mone receptor-positive breast cancer) [5].
Pulmonary oedema is not uncommon in patients
undergoing chemotherapy as many regimens include
large amounts of fluid in order to decrease the local tox-
icity of the drugs. Particularly in patients with renal
insufficiency this may lead to a fluid overload resulting
in pulmonary interstitial or even intraalveolar oedema
(Fig. 7).
Progression of malignancy in the lung
In cancer patients pulmonary complications of the ther-
apy, obviously need to be differentiated from pulmonary
manifestations or progression of malignancy.
Lymphangitic carcinomatosis (LAC) usually presents
with dyspnoea, unproductive cough and may be associ-
ated with signs of inflammation. It, typically, manifests
radiologically as reticular and linear pattern due to
smooth or nodular thickening of interlobar and inter-
lobular septae and thickening of bronchovascular bun-
dles. It may be associated with pleural effusion with or
without nodular pleural thickening, lymphadenopathy
and other signs of tumour progression.
Malignant lymphoma may involve the lung either
with a solitary lesion (extranodal manifestations) or dif-
fuse lung involvement (stage IV disease). Pulmonary
lymphoma may present as well- or ill-defined solitary or
multiple nodules, areas of consolidation mimicking
pneumonia or interstitial pattern (thickened septae and
bronchovascular bundles).
Pulmonary metastases usually present as multiple,
well-defined solid nodules with a predominance in the
lower lung zones and the lung periphery. Ill-defined,
solitary or central nodules are less common. Typically,
metastases exhibit a nodular pattern with different-size
nodules (Fig. 8).
Fig. 2 Drug-induced lung disease with a NSIP pattern (non-specific
interstitial pneumonia). Patient with chemotherapy for bladder
cancer. Chest CT at the level of the right pulmonary artery at lung
window. Diffuse bilateral peripheral reticular pattern, ground glass
and some consolidation
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Imaging techniques
Chest radiography
Conventional radiography should be performed if at all
possible erect in two views (p.a. and lateral). A high
quality chest radiograph is appropriate to confirm or ex-
clude pulmonary disease in most clinical settings.
If the patient’s clinical situation allows only a.p. supine
chest radiography this may be insufficient because of its
limitations in both sensitivity and specificity for pulmon-
ary disease and chest CT may be required.
Is there a role for chest CT in patients with a
normal chest radiograph?
There are clinical settings in which chest CT is indicated
even in the presence of a normal high quality chest
radiograph in two views.
In patients with severe neutropenia (<1000 neutro-
phil granulocytes/μl) the usual response to organisms
causing pulmonary infection of neutrophils migrating to
the site of infection causing an inflammatory infiltrate
composed of fluid, neutrophils, macrophages and lym-
phocytes may not be possible due to a lack of the cellu-
lar elements.
In this situation imaging is not aimed at demonstrating
the host’s response to the infection (i.e. inflammatory in-
filtration presenting as consolidation or ground glass
opacity) but rather the local effects of the offending
organism itself such as local haemorrhage or vascular
occlusion due to invasion by the organism.
Patients with prolonged (>5 days) neutropenia are par-
ticularly susceptible to fungal infection (aspergillus,
candida etc.) and antifungal therapy is associated with
significant toxicity. Therefore, it is advocated to perform
chest CT even in the presence of a normal chest radio-
graph, particularly if empirical antibacterial therapy does
not result in a resolution of the symptoms (Fig. 4).
Another specific situation in which chest radiography
may be insufficient to demonstrate significant pulmon-
ary disease is pneumocystis jirovecii pneumonia
(PCP). In the early stages of the infection this organism
causes diffuse ground glass which may be impossible to
detect even at high quality erect two view chest radiog-
raphy. The only but obviously unspecific sign at chest
radiography may be decreased depth of inspiration com-
pared to previous chest films due to a decrease in elasti-
city of the pulmonary parenchyma.
Therefore, in patients with suspected PCP chest CT
may be helpful to demonstrate the typical pattern of
Table 1 Risk factors predisposing to infection with different organisms
Involved cell
line
Granulocytes, Monocytes B-Lymphocytes T-Lymphocytes
Immune defect Unspecific cellular defense Antibody-deficiency Specific cellular defense
Disease Solid tumours myeloid leukaemia short
term (<5 d) neutropenia
B-cell-lymphoma, B-ALL,
lymphotoxic therapy (steroids)
T-cell-lymphoma, T-ALL, lymphotoxic therapy
continuous immunosuppression, allogenic stem
cell transplant, organ transplant, T-cell-specific
drugs (Alemzutumab, Antithymocyte globulin)
Organisms Bacteria (gram+, gram-) in neutropenia > 10 d
also fungi (lung: Aspergillus, liver/spleen: Candida,
pleura/paranasal sinus: Mucormyces)
Bacteria (gram +, gram-) Pneumocystis jirovecii (PCP), viruses, fungi
(Toxoplasma, Listeria, Coccidiomyces)
Pneumocystis jirovecii (PCP)
Adapted from: Diederich S and Giagounidis A (2014) Therapy-associated changes of the lung and pleura in cancer patients. RadiologieUp2date 14: 331-346
Fig. 3 Bacterial pneumonia. Patient with chemotherapy for Burkitt-
Lymphoma. a Chest radiograph p.a.: Consolidation projected over
the right lateral upper lung zone. b Chest CT at lung window:
heterogenous consolidation in the posterior segment of the right
upper lobe and the apical segment of the right lower lobe
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ground glass opacity sparing the lung periphery with no
associated lymphadenopathy or pleural effusion (Fig. 6).
CT technique
Intravenous contrast medium
If the detection and/or classification of pulmonary path-
ology is the sole indication for imaging unenhanced CT
is usually sufficient.
Intravenous administration of contrast medium with a
delay sufficient to allow enhancement of soft tissues
(40–70 s) may be performed if assessment of mediasti-
num, hila, pleural space or chest wall is required (tumour
staging, soft tissue infection etc.)
In patients in whom the differential diagnosis includes
pulmonary embolism (dyspnoea, pleuritic chest pain
etc.) intravenous contrast injection with a delay appro-
priate for CT pulmonary angiography may be required.
Dose considerations
As many cancer patients are treated with a curative in-
tent and these patients usually undergo several imaging
studies involving radiation exposure the potential for
dose reduction needs to be considered in every individ-
ual study, particularly at CT.
In addition to standard approaches such as iterative
reconstruction tailoring of the radiation dose to the indi-
vidual clinical situation is mandatory:
For example, in a patient with severe dyspnoea, in
whom the differential diagnosis includes pulmonary in-
fection, toxicity, and pulmonary embolism a contrast
enhanced protocol with reduced kilovoltage (e.g. 80 kV)
may be considered.
Unenhanced CT can usually be performed with signifi-
cantly reduced tube current (20–40 mAs). The limita-
tion of low-dose CT in detection of subtle density
differences particularly ground glass may be overcome
by using a narrower lung window setting than usually
(window width 1000 Hounsfield Units (HU) instead of
1500 HU).
Image acquisition and reconstruction
The technique of choice is multidetector helical CT, if
possible during suspended inspiration.
Image reconstruction should be performed in the axial
plane with a slice thickness of 3 - 5 mm in lung and soft
tissue reconstruction algorithms.
Axial images at the minimal available slice thickness
(e.g. 1 mm) should be reconstructed in the high-
resolution kernel to allow for maximum spatial reso-
lution and high-quality multiplanar coronal and sagit-
tal reformations.
In our institution routine reporting is done on the basis
of 5 sets of images, namely axial 3–5 mm images at soft
Fig. 4 Viral pneumonia from cytomegaly virus. Patient with chemotherapy for Non-Hodgkin Lymphoma. a, b Chest CT at the level of the aortic
arch (a) and the pulmonary trunk (b) at lung windows. Bilateral reticular-nodular interstitial pattern, consolidation and ground glass
Fig. 5 Angioinvasive pulmonary aspergillosis. Patient with
chemotherapy for acute myeloid leukaemia. Chest CT at the level of
the apical segment of the left upper lobe at lung window: Focal
area of consolidation surrounded by a “halo” of ground glass
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tissue and lung windows, thin-slice mm axial images and
coronal and sagittal reformations at lung window (Table 2).
In the presence of a patient with significant dyspnoea
and a normal chest CT in suspended inspiration, add-
itional images obtained at end-expiration may be useful
to detect small airways disease which may only present
as air-trapping at expiratory images. Small airways disease
may be due to infection or toxicity of oncologic drugs.
Image display
On the reporting workstation images are routinely dis-
played with 4 images simultaneously:
– Axial 3–5 mm mediastinal window (400/20 HU:
unenhanced, 400/40 HU enhanced)
– Axial 3–5 mm lung window (1500/- 600 HU)
– Coronal 3–5 mm lung window
– Sagittal 3–5 mm lung window
For analysis of the lung morphology, particularly in
nodular, reticular and linear patterns, 1-2 mm axial
(occasionally sagittal and coronal) images at lung windows
are viewed.
Rarely maximum intensity projection images are recon-
structed to better delineate micronodular pattern.
Interpretation
Adequacy of the study
As patients with pulmonary disease even if correctly
instructed may not be able to hold their breath at end-
inspiration, the degree of inspiration is the first aspect of
the analysis.
A reliable sign of a good inspiratory effort is an ovoid
(convex) shape of the thoracic trachea. During expiration
the posterior membranous part of the trachea (pars
membranacea) is flat or even concave.
In cases with poor inspiration apparent ground glass
opacity of the lung may be only due to expiratory effects.
In these cases “ground glass” is usually observed in the
posterior aspects of pulmonary lobes with a ventrodorsal
gradient of density and may not be mistaken for true
pathology. In these cases it may be appropriate to try
and repeat the study with a better inspiratory effort.
Analysis of radiological patterns
Morphology
Diffuse pathology of the lung demonstrated at CT is
usually classified in 4 categories. This approach is also
useful in suspected pulmonary complications of onco-
logic therapy.
Consolidation/ground glass
In diffuse pulmonary infiltration there are two different
morphologic types: a density that obscures pulmonary
vessels and bronchial walls at lung window settings is
termed “consolidation” whereas a less pronounced degree
Fig. 6 Pneumocystis jirovecii pneumonia. Patient with adjuvant chemotherapy for breast cancer. Chest CT at the level of the lung apex (a),
tracheal bifurcation (b), apical segments of the lower lobes (c) and the dome of the right diaphragm (d) at lung windows: Diffuse, symmetrical,
bilateral ground glass sparing the lung periphery both in the axial plane as well as lung apices and bases
Table 2 Standard image reconstruction and display
Axial plane 3–5- mm standard reconstruction kernel (soft tissues)
3–5- mm high-resolution reconstruction kernel (lung)
1–2 mm high-resolution reconstruction kernel
(lung, multiplanar reformation)
Sagittal plane 1–5 mm high-resolution kernel
Coronal plane 1–5 mm high-resolution kernel
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of increased density which does not obscure pulmonary
vessels and bronchial walls is termed “ground glass”.
In consolidation the air in the peripheral airways bron-
chioles and alveoli is completely displaced by a solid
substance such as pus, haemorrhage, tumour cells etc.,
whereas ground glass density is due to partial replace-
ment of air independent of the type of substance.
Nodular pattern
If a diffuse nodular pattern is present differentiation is
made between three main types of pulmonary nodules
depending on the exact location of the nodules with re-
spect to the secondary pulmonary nodule, the smallest
anatomical subunit of the lung:
Centrilobular (airspace) nodules are usually ill-defined
and are located in the centre of the secondary pulmonary
nodules and are, thus, clearly separate from the costal
pleura.
Perilymphatic nodules are usually well-defined and are
located along the intralobular septae and the visceral
pleura and, thus, the interlobar fissures as well along the
bronchovascular bundles.
Nodules with random distribution are usually
well-defined and are located in all parts of the lung
with respect to the secondary lobule.
Linear, reticular pattern
A linear or reticular pattern is usually caused by sub-
strate accumulating in the inter- and intralobular septae.
The finding is not specific as the substrate may represent
fluid (interstitial oedema), inflammatory exudate (intersti-
tial pneumonia) or tumor (lymphangitic carcinomatosis:
LAC).
The distribution may help to distinguish oedema
which is usually symmetrical with a dorsal and basal pre-
dominance from interstitial pneumonia and LAC which
are usually asymmetrical or even unilateral.
The time course at follow-up may also help in the dif-
ferentiation: Interstitial pattern in oedema may change
rapidly (<24 h), in infection changes are less rapid (days)
whereas in LAC findings remain relatively constant for
days or weeks.
Decreased attenuation
This feature summarizes emphysema, pulmonary cysts
and air-trapping. Emphysema and pulmonary cysts do
not usually represent complications of oncologic ther-
apy. Bronchiolitis presenting as air-trapping (see above:
expiratory CT) may be due to viral and bacterial infec-
tion or drug toxicity (e.g. methotrexate). Some mild de-
gree of air-trapping is also observed in normal lung and
other pulmonary diseases.
Fig. 7 Pulmonary interstitial and alveolar oedema. Patient with
adjuvant chemotherapy for breast cancer. a, b chest CT at the level
of the aortic arch (a) and the right lower pulmonary vein (b) at lung
windows: Diffuse bilateral reticular pattern due to interlobular septal
thickening, some mild ground glass, mild thickening of bronchovascular
bundles and bilateral pleura l effusions, right larger than left
Fig. 8 Multiple pulmonary metastases. Patient with sigmoid
carcinoma. Chest CT at the level of the right inferior pulmonary vein
at lung window: Multiple small pulmonary nodules with different
sizes and random distribution in all lung lobes
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Distribution
The distribution of pathological findings within the
lung may be useful to differentiate between different
conditions.
Apical versus basal predominance as well as peripheral
versus central localisation are helpful in distinguishing
between different diseases with similar morphological
changes.
The fact, that abnormalities may cross anatomical bor-
ders and at the same time are confined to a known or
presumptive radiation port is almost pathognomonic of
radiation pneumonitis.
Analysis of an individual case
As a first step the degree of inspiration needs to be
assessed by checking whether the trachea appears ovoid
with a convex pars membranacea indicating an appropri-
ate degree of inspiration or whether the posterior aspect
is flat or even concave indicating an expiratory scan. If
so, apparent ground-glass density may have to be dis-
carded, particularly when observed in the posterior por-
tions of each pulmonary lobe (see above).
Secondly, it needs to be checked which of the morpho-
logical patterns of lung pathology is the predominant
type as in most pathologic conditions a mixture of dif-
ferent patterns is observed.
Consolidation/ground glass
In increased diffuse attenuation manifesting either as
ground glass opacity or consolidation (see above) additional
aspects may help to suggest the aetiology.
Predominant consolidation with some ground glass
and air space (centrilobular) nodules suggests bacterial
pneumonia.
A mixture of consolidation and ground glass in
combination with nodular and/or reticular pattern
is commonly observed in viral pneumonia.
Focal areas of consolidation surrounded by a “halo”
of ground glass is the typical finding in angioinvasive
aspergillosis in the appropriate clinical setting (severe
neutropenia and fever that does not respond the antibac-
terial therapy).
Ground glass or consolidation in an area of the lung
that has been exposed to radiation therapy with the ap-
propriate dose and time interval is suggestive of radiation
pneumonitis
Predominant or pure ground glass with a diffuse,
bilateral and central location is typical of pneumocystis
jirovecii pneumonia (PCP).
Predominant ground glass with an upper lobe pre-
dominance suggests acute hypersensitivity pneumon-
itis as one manifestation of drug-induced lung disease.
The subacute stage is characterized by a combination
of ground glass and air-space nodules.
Linear or reticular pattern
Bilateral symmetrical linear and reticular pattern,
usually with some ground glass and a predominance in
the dependend portion of the lung is suggestive of inter-
stitial oedema. It is usually associated with extrapulmon-
ary findings of right heart failure such as bilateral pleural
effusions (usually right > left), ascites, distension of SVC
and IVC and gall bladder wall oedema.
The combination of linear/reticular pattern with
ground glass, consolidation and/or nodular pattern is
typical of viral pneumonia.
Linear/reticular pattern often with a nodular appear-
ance of the thickened septae with an asymmetric or
unilateral distribution with or without thickening of the
bronchovascular bundles is found in lymphangitic spread
of tumour.
A predominant reticular pattern with a basal and
peripheral distribution in combination with ground
glass is found in drug-induced lung disease with a NSIP
pattern (non specific interstitial pneumonia).
Nodular pattern
Centrilobular nodules are either due to inflammation
(bronchiolitis/vasculitis) or spread of tumour along the
alveolar septae (adenocarcinoma with predominant le-
pidic growth (formerly: bronchioloalveolar carcionoma).
Bronchiolitis may be due to infection (viral, bacterial,
tuberculosis bronchiolitis) or may be drug induced,
e. g. methotrexate). Vasculitis in this setting may be
drug induced.
Random pattern of nodular disease is usually due to
haematogenous spread of infection (candida, tubercu-
losis) or tumour (pulmonary metastases). Whereas the
nodules in infection tend to have a similar size, random
distribution of pulmonary nodules with different sizes
suggest metastases. Nodule growth as demonstrated at
follow-up or by review of a previous CT examinations is
highly suggestive of malignancy (metastases) whereas new
nodules can represent both metastases and infection.
Perilymphatic nodular pattern is found in lymphangitic
carcinomatosis or unrelated diseases such as sarcoidosis or
silicosis/coal worker’s pneumoconiosis. This pattern may
also be due to benign intrapulmonary lymph nodes.
In lymphangitic carcinomatosis there is usually a com-
bination with linear/reticular pattern and thickening of
bronchovascular bundles. The distribution is mostly
asymmetrical or even unilateral. Lymphadenopathy and
(often unilateral) pleural effusion are common.
In sarcoidosis a combination with linear/reticular pattern
and thickening of bronchovascular bundles in a symmetric
distribution with central predominance is common.
Bilateral hilar as well as mediastinal lymphadenop-
athy is also common, whereas pleural effusion is very
uncommon in sarcoidosis.
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In silicosis the nodular pattern is found in an upper
lobe and central predominance, association with hilar
and mediastinal lymphadenopathy (with longer duration
with peripheral calcification (eggshell lymph nodes) is
very common. Pleural effusion is uncommon.
Several larger nodules, often with cavitation and ill-
defined margins are typically found in septic emboli from
bacterial infection in the venous system (central line, port-
a-cath, septic thrombosis) or the right heart/endocarditis).
Extrapulmonary findings
Pleural effusion
Bilateral pleural effusion is a common presentation of
(right) cardiac failure, renal failure or hyperhydration
which may be therapy-induced (cardiotoxic drugs,
nephrotoxic drugs, large amounts of fluid during chemo-
therapy). In this setting the amount of pleural effusion is
usually larger in the right than in the left pleural space.
There is an association with other signs of right heart
failure such as pericardial effusion, ascites, dilatation of
SVC, IVC and hepatic veins and gallbladder wall oedema.
Unilateral pleura effusion is usually not due to the
courses listed above but either pleural carcinomatosis or
pleural infection. Diffuse pleural thickening with or with-
out contrast enhancement (“split pleura sign”) may be
found in infection, chronic non-infected effusion or pleura
carcinomatosis. Nodular pleura thickening is almost path-
ognomonic of pleural tumour spread (carcinomatosis,
lymphomatosis, sarcomatosis). This may be associated
with lymphangitic carcinomatosis and lymphadenopathy.
Lymphadenopathy
Mildly enlarged lymph nodes are usually found in
heart failure but also in drug-induced lung disease, radi-
ation pneumonitis and many other unrelated conditions.
More pronounced lymphadenopathy is found in bac-
terial and viral pneumonia with the location of enlarged
lymph nodes according to the lymphatic drainage of the
infected pulmonary lobe or segment.
The most pronounced lymph node enlargement if
found in malignant lymphadenopathy. Lymph nodes
with a diameter > 3 cm are usually malignant (malignant
lymphoma, lymph node metastases).
Lymphadenopathy with rim-enhancement is typical
of tuberculous lymphadenitis which may occur without
pulmonary manifestations of tuberculosis.
Lymphadenopathy is uncommon in pneumocystis jirovecii
pneumonia (PcP) or fungal infection (candida, aspergillus).
Lymphadenopathy due to unrelated diseases such as
collagen vascular disease etc. is usually mild.
Tumour manifestations
Extrapulmonary tumour manifestations need to be observed
when interpreting pulmonary findings. Although possible it
is unlikely that new or progressive pulmonary pathology pre-
sents malignant disease such as (LAC or metastases) when
other tumour manifestations (axillary lymph node metasta-
ses, liver metastases, skeletal metastases) respond to therapy.
Formulating the report
The report should, obviously, include the clinical ques-
tion so as to to address it in the conclusion.
The examination technique should be described, par-
ticularly whether the CT examination was performed
with or without intravenous contrast injection.
The quality of the examination (inspiration, breathing
artefacts) should be mentioned to show potential limita-
tions of the study.
The morphology of pulmonary and extrapulmonary
pathology should be described to allow re-evaluation if
new aspects of the clinical context are identified.
Incidental findings that are not known are uncommon
when cancer patients are imaged for potential complica-
tions of therapy as previous imaging (staging examina-
tions) are usually available.
Conclusion
In the setting of suspected complications of cancer ther-
apy usually a synopsis of clinical information (signs
and symptoms, body temperature), history (date and
dose of radiation therapy, radiation portal, date and dose
of systemic therapies, other relevant diseases such as
DVT), laboratory findings (CRP, leucocytes, broncho-
alveolar lavage (BAL) results: lymphocytic, neutrophil
alveolitis, organisms, evidence of viral pneumonia) and
imaging findings is made.
As a definite diagnosis can be rarely made, the degree
of confidence in the diagnosis needs to be addressed.
Recommendation
As there are few pathognomonic CT findings in the set-
ting of suspected pulmonary complications of oncologic
therapy recommendations on further procedures should
be made in the report.
Short-term follow-up (days) may be useful to differ-
entiate between oedema versus infection versus tumour
progression as oedema may exhibit marked changes
within 24 h with the appropriate therapy, infection usually
requires days for improvement or deterioration of pul-
monary abnormalities whereas tumour manifestations
remain relatively stable for weeks.
In suspected drug toxicity discontinuation of the po-
tentially offending agent with or without steroid therapy
and usually parallel antibiotic therapy to cover potential
infection may be advocated. Additional non-radiological
diagnostics procedures such as bronchoalveolar lavage
(BAL), transbronchial biopsy (TBB) or percutaneous
biopsy may be recommended and guided by CT.
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Summary
In cancer patient during or following oncologic therapies
with respiratory symptoms and pulmonary pathology at
chest CT the differential diagnosis includes infection,
therapy-induced disease and tumour progression.
Although CT morphology may be typical or even pathog-
nomonic in some conditions the diagnosis is usually made
by a synopsis of imaging, clinical and laboratory features.
Close communication with referring colleagues and a
good knowledge of potential side effects of therapeutic
concepts, their time course and CT morphology is crucial
in the differential diagnosis.
Appendix
Important features in different complications of oncologic
therapy
This list contains some – but certainly not all – features
that may help in the diagnosis
Bacterial pneumonia
Asymmetrical/unilateral









Prolonged neutropenia, not responsive to antibacterial
therapy
Chest radiograph may be normal
Invasive pulmonary aspergillosis: consolidation with
halo of ground glass, infarct-löike pattern
Candida. Multiple diffuse, bilateral, random nodules,
ususally candidiasis of mouth, oesophagus, vagina etc.
Pneumocystis jirovecii pneumonia (PCP)
Severe dyspnoea/hypoxia
Chest radiograph may be normal




Diffuse, bilateral reticular pattern in the dependend




Cryptogenic organizing pneumonia (COP)
Focal areas of consolidation
Not responsive to antibacterial therapy
May be associated with radiation therapy
May be a manifestation of drug-induced lung
disease
Radiation pneumonitis
Ground glass or consolidation limited to the radiation
port
6 weeks or later after threshold of 30–40 Gy to the
involved lung has been reached
Typical time course: ground glass - consolidation -
fibrosis
Drug-related lung disease
Think of it !
www.pneumotox.org
may manifest with large variety of pulmonary patterns
including NSIP, hypersensitivity pneumonitis, COP,
oedema, haemorrhage, bronchiolitis, vasculitis, pleural
effusion etc.
diagnosis of exclusion
therapy: cessation of offending drug +/- steroids
Lymphangitic carcinomatosis (LAC)







BAL: Bronchoalveolar lavage; COP: Cryptogenic organizing pneumonia;
CRP: C-reactive protein; DVT: Deep venous thrombosis; Gy: Gray;
HU: Hounsfield Units; iMRT: Intensity-modulated radiation therapy;
IPA: Invasive pulmonary aspergillosis; IVC: Inferior vena cava; kV: Kilovolt;
LAC: Lymphangitic carcinomatosis; mAs: Milliampereseconds; NSCLC: Non
small-cell lung cancer; NSIP: Non-specific interstitial pneumonia;
PCP: Pneumocystis jirovecii pneumonia; PE: Pulmonary embolism;
SVC: Superior vena cava; TBB: Transbronchial biopsy.
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